substanti
proport
cap
mix
bacteri
viral
infect
overdiagnosi
mild
moder
cap
lead
overtreat
difficulti
differenti
bacteri
viral
pneumonia
often
lead
unnecessari
antibiot
use
current
guidelin
pediatr
infecti
diseas
societi
pid
infecti
diseas
societi
america
idsa
recommend
amoxicillin
mgkgd
oral
dose
primari
therapi
presum
bacteri
pneumonia
azithromycin
mgkg
day
follow
mgkg
daili
day
primari
therapi
presum
atyp
pneumonia
children
younger
year
age
year
older
children
age
year
older
presum
bacteri
cap
clinic
laboratori
radiograph
evid
distinguish
bacteri
cap
atyp
cap
pidsidsa
guidelin
note
macrolid
ad
blactam
antibiot
much
pediatr
cap
guidelin
base
evid
poor
moder
qualiti
mani
gap
evid
remain
main
challeng
diagnosi
cap
first
definit
cap
particularli
young
children
bacteri
viral
infect
occur
similar
frequenc
overdiagnosi
mild
symptom
sign
may
lead
unnecessari
antibiot
use
second
identif
caus
pathogen
frequent
impract
inadequ
children
failur
isol
organ
result
unnecessari
antibiot
use
problem
affect
manag
cap
lead
emerg
resist
result
overtreat
manag
decis
complic
random
control
trial
children
evalu
differ
antibiot
therapi
treatment
durat
although
guidelin
exist
often
base
poorqual
evid
challeng
gener
pediatrician
recogn
lower
respiratori
tract
ill
refer
hospit
sever
appropri
treat
antibiot
bacteri
pneumonia
suspect
review
focus
practic
issu
clinic
relev
gener
pediatrician
includ
elicit
patient
histori
examin
keep
mind
infect
commonli
seen
also
emerg
infecti
diseas
less
frequent
seen
sever
occur
first
key
clinic
issu
diagnos
cap
children
determin
pathogen
respons
discrep
definit
cap
depend
whether
consider
epidemiolog
sensit
criteria
regulatori
specif
tabl
caus
agent
children
difficult
identifi
howev
clue
histori
may
help
point
toward
certain
infecti
pathogen
tabl
caus
pediatr
pneumonia
usual
base
age
best
predictor
avail
tabl
streptococcu
pneumonia
haemophilu
influenza
type
b
hib
character
bacteria
predomin
respons
case
fatal
pneumonia
children
howev
widespread
introduct
hib
pneumococc
conjug
vaccin
led
signific
declin
especi
hib
although
streptococcu
pneumonia
still
predomin
bacteria
isol
bacteri
cap
children
increas
recognit
preval
mix
bacteri
viral
infect
document
case
pneumonia
atyp
organ
eg
mycoplasma
pneumonia
chlamydia
pneumonia
account
third
case
new
chlamydialik
organ
simkania
negevensi
associ
bronchiol
pneumonia
children
also
identifi
bacteria
cultur
sputum
gastric
aspir
posit
tuberculin
skin
test
interferon
g
releas
assay
continu
next
page
older
year
virus
account
pediatr
cap
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
commonli
identifi
studi
singleton
colleagu
recov
respiratori
virus
alaskan
children
younger
year
hospit
respiratori
infect
casecontrol
studi
children
rsv
piv
human
metapneumoviru
hmpv
influenza
significantli
common
hospit
case
control
children
rhinoviru
adenoviru
coronaviru
high
occurr
asymptomat
carriag
third
asymptomat
children
harbor
rhinoviru
complic
frequent
detect
respiratori
virus
caus
natur
mani
respiratori
virus
pneumonia
particularli
one
identifi
sensit
new
molecular
diagnost
remain
unclear
howev
rhinoviru
identif
associ
bronchiol
asthma
wheez
hmpv
isol
recov
isol
nasopharyng
throat
specimen
hospit
children
children
cap
human
bocaviru
first
describ
detect
clinic
sampl
mainli
infant
young
children
detect
serum
stool
suggest
viru
may
caus
system
diseas
wu
ki
polyomavirus
detect
respiratori
tract
sampl
adult
children
subsequ
shown
present
respiratori
secret
patient
acut
respiratori
ill
sever
acquir
respiratori
syndrom
sar
associ
coronaviru
first
novel
coronaviru
character
among
success
novel
coronavirus
decad
use
sensit
revers
transcript
polymeras
chain
reaction
pcr
assay
dominguez
colleagu
detect
coronaviru
rna
pediatr
respiratori
specimen
coronavirusposit
patient
evid
lower
respiratori
tract
infect
twentysix
percent
group
present
vomit
diarrhea
meningoenceph
seizur
suggest
coronaviru
may
system
involv
previous
believ
fungal
pathogen
histoplasma
coccidioid
blastomyc
cryptococcu
caus
pneumonia
immunocompromis
patient
popul
may
caus
clinic
ill
immunocompet
host
usual
present
cap
blastomyc
caus
prolong
fever
respiratori
symptom
mimic
prolong
cap
howev
cryptococcu
gattii
infect
immunocompet
host
caus
increas
number
infect
us
pacif
northwest
sinc
detect
southeastern
unit
state
pathogen
caus
cryptococcoma
lung
report
infect
patient
document
pneumonia
mycobacterium
tuberculosi
nontubercul
mycobacteria
likewis
caus
cap
tend
limit
peopl
highrisk
exposur
similarli
highrisk
exposur
suggest
specif
caus
outlin
tabl
symptom
fever
chill
cough
pneumonia
overlap
significantli
spectrum
condit
bacteri
sepsi
sever
anemia
make
differenti
diagnos
challeng
sign
crackl
egophoni
specif
often
absent
clinic
pneumonia
children
chest
radiographi
consid
gold
standard
confirm
pneumonia
also
question
benefit
children
discuss
later
limit
diagnosi
reflect
variou
definit
pediatr
cap
exist
see
tabl
none
consid
suffici
sensit
specif
valid
children
exampl
world
health
organ
criteria
mild
moder
cap
base
cough
breath
difficulti
ageadjust
tachypnea
definit
place
cap
type
lower
respiratori
tract
diseas
clinic
featur
children
cap
vari
age
child
although
none
specif
ceveymacherel
colleagu
show
fifth
patient
diagnos
cap
defin
guidelin
complet
normal
breath
sound
admiss
auscult
rule
poorli
sensit
specif
diagnos
guidelinedefin
cap
young
children
howev
guidelin
reli
sole
respiratori
rate
use
criteria
diagnosi
pneumonia
lower
respiratori
tract
infect
respiratori
rate
shown
less
sensit
specif
first
day
ill
studi
defin
pneumonialow
respiratori
tract
infect
presenc
crepit
crackl
wheez
bronchial
breath
chest
radiograph
cxr
abnorm
respiratori
rate
less
breathsmin
seen
children
older
month
diagnosi
pneumonia
canadian
guidelin
regard
oxygen
good
indic
sever
diseas
oxygen
satur
recommend
infecti
diseas
societi
america
idsa
guid
referr
care
diagnost
test
clinic
featur
reliabl
distinguish
viral
bacteri
atyp
pneumonia
pneumococc
pneumonia
associ
histori
fever
breathless
sign
tachypnea
indraw
toxic
appear
featur
indistinguish
staphylococc
pneumonia
begin
ill
similarli
mycoplasma
pneumonia
associ
cough
chest
pain
wheez
symptom
wors
sign
well
nonrespiratori
symptom
arthralgia
headach
studi
success
distinguish
viral
bacteri
cap
type
cap
clinic
approach
common
bacteri
infect
sign
alon
addit
mani
children
cap
mix
bacteri
viral
infect
mycoplasma
pneumonia
common
children
age
year
younger
typic
character
slow
progress
sore
throat
lowgrad
fever
cough
develop
day
although
children
abrupt
onset
symptom
higher
fever
pattern
may
help
distinguish
pneumococc
staphylococc
pneumonia
influenc
treatment
decis
rapid
laboratori
test
allow
clear
distinct
classic
bacteri
atyp
pneumonia
neither
idsa
british
thorac
societi
bt
recommend
cxr
confirm
suspect
cap
patient
well
enough
treat
outpati
set
cxr
children
unlik
adult
pneumonia
may
show
abnorm
especi
taken
onset
ill
beyond
provid
radiograph
evid
opacif
use
cxr
limit
shown
correl
clinic
sign
help
differenti
bacteri
viral
pneumonia
prospect
studi
switzerland
enrol
patient
found
patient
radiograph
consolid
poor
correl
radiograph
find
diminish
breath
sound
associ
sever
caus
pneumonia
prospect
studi
unit
kingdom
clark
colleagu
show
lobar
cxr
chang
associ
sever
studi
brazil
upper
lobe
involv
shown
specif
posit
predict
valu
sever
children
age
year
younger
hospit
cap
wherea
idsa
guidelin
support
posteroanterior
pa
later
cxr
patient
suspect
document
hypoxemia
signific
respiratori
distress
fail
initi
cours
antibiot
therapi
bt
guidelin
recommend
later
cxr
perform
routin
recommend
base
retrospect
studi
unit
state
indic
frontal
cxr
sensit
specif
lobar
consolid
would
underdiagnos
nonlobar
infiltr
case
investig
consid
clinic
implic
unclear
howev
patient
hospit
manag
cap
box
pa
later
cxr
ensur
infiltr
detect
assess
pleural
effus
followup
cxr
unnecessari
children
recov
unev
episod
cap
obtain
children
improv
clinic
progress
symptom
clinic
deterior
hour
antibiot
therapi
patient
bacteri
pneumonia
present
lobar
infiltr
fig
interstiti
infiltr
found
bacteri
well
viral
atyp
pneumonia
mycoplasma
pneumonia
pneumonia
diffus
infiltr
radiolog
proport
clinic
find
lobar
consolid
atelectasi
nodular
infiltr
hilar
adenopathi
also
describ
streptococcu
pneumonia
pneumonia
present
round
infiltr
see
fig
also
seen
bacteria
microbiolog
recoveri
sampl
directli
infect
region
lung
gold
standard
although
less
invas
sampl
method
usual
use
achiev
diagnosi
see
tabl
found
definit
use
differenti
caus
sever
cap
colleagu
studi
children
show
increas
serum
nonspecif
inflammatori
marker
wbc
crp
esr
pct
significantli
associ
radiograph
evid
cap
howev
role
studi
screen
bacteri
viral
cap
limit
studi
lahti
colleagu
involv
children
month
older
show
induc
sputum
product
inhal
hyperton
salin
minut
aspir
expector
sputum
sampl
provid
goodqual
sputum
specimen
microbiolog
yield
howev
practic
rel
laborintens
approach
busi
outpati
clinic
debat
new
molecular
diagnost
test
becom
avail
particularli
rapid
antigen
detect
respiratori
virus
despit
develop
onequart
onethird
patient
still
fail
yield
obviou
caus
indic
sever
pediatr
cap
streptococcu
pneumonia
common
bacteri
pathogen
studi
remain
challeng
identifi
less
children
pneumonia
bacterem
definit
noninvas
accur
test
urinari
antigen
test
streptococcu
pneumonia
recommend
idsa
diagnosi
pneumococc
pneumonia
children
falseposit
test
common
like
attribut
nasopharyng
carriag
diagnosi
mycoplasma
pneumonia
infect
made
test
igm
mycoplasma
pneumonia
serum
plasma
enzymelink
immunosorb
assay
elisa
pcr
test
nasal
throat
sputum
specimen
pcr
seem
detect
mycoplasma
infect
igm
elisa
test
singl
standard
test
use
across
studi
definit
data
difficult
obtain
rapid
igm
test
kit
assess
may
promis
way
rapidli
detect
mycoplasma
infect
none
valid
highli
sensit
specif
multipl
studi
main
issu
gener
pediatrician
manag
suspect
pediatr
cap
whether
treat
antibiot
decis
complic
difficult
distinguish
bacteri
viral
pneumonia
henc
decid
whether
antibiot
may
warrant
also
random
control
trial
guid
antibiot
choic
durat
age
best
predictor
caus
pediatr
pneumonia
guidelin
treatment
typic
categor
age
suspect
pathogen
bt
guidelin
recommend
children
clear
clinic
diagnosi
pneumonia
receiv
antibiot
given
bacteri
viral
pneumonia
reliabl
differenti
howev
viral
pathogen
respons
clinic
diseas
preschoolag
children
cap
idsa
routin
recommend
antimicrobi
therapi
group
streptococcu
pneumonia
promin
bacteri
pathogen
across
age
group
henc
amoxicillin
recommend
firstlin
therapi
previous
healthi
appropri
immun
patient
hib
vaccin
offer
protect
nontyp
haemophilu
influenza
alter
choic
empir
antibiot
therapi
vaccin
children
suspect
bacteri
pneumonia
atyp
bacteri
pathogen
mycoplasma
pneumonia
promin
schoolag
children
older
patient
macrolid
therapi
recommend
compat
find
gener
base
clinic
find
howev
highqual
data
effect
macrolid
antibiot
treatment
children
mycoplasma
pneumonia
recommend
treatment
macrolid
condit
list
weak
recommend
pidsidsa
guidelin
bacterialvir
coinfect
well
document
occur
influenza
streptococcu
pneumonia
staphylococcu
aureu
group
streptococcu
henc
children
seriou
viral
lower
respiratori
tract
infect
may
still
benefit
empir
therapi
bacteri
agent
adjunct
treatment
corticosteroid
studi
shown
proven
benefit
outcom
summari
pidsidsa
guidelin
cap
children
continu
recommend
amoxicillin
mgkgd
oral
dose
primari
therapi
presum
bacteri
pneumonia
azithromycin
mgkg
day
follow
mgkg
daili
day
primari
therapi
presum
atyp
pneumonia
children
younger
year
age
year
older
children
age
year
older
presum
bacteri
cap
clinic
laboratori
radiograph
evid
distinguish
bacteri
cap
atyp
cap
pidsidsa
guidelin
note
macrolid
ad
blactam
antibiot
note
earlier
definit
clinic
laboratori
radiograph
find
distinguish
bacteri
atyp
cap
decis
use
add
macrolid
remain
base
overal
indic
combin
find
rather
clearli
defin
set
criteria
base
find
asid
influenza
data
prospect
control
studi
antivir
therapi
virus
associ
pediatr
cap
adamantan
neuraminidas
inhibitor
effect
suscept
strain
influenza
neuraminidas
inhibitor
effect
suscept
strain
influenza
b
substanti
genet
variat
occur
influenza
year
year
influenza
viru
strain
becom
resist
either
class
antivir
agent
strain
influenza
isol
sinc
season
adamantineresist
recommend
dose
antivir
agent
season
influenza
develop
fulli
suscept
strain
evalu
trial
treatment
provid
earli
usual
within
hour
onset
symptom
degre
benefit
provid
treatment
hour
symptom
defin
studi
look
appropri
durat
antimicrobi
therapi
cap
children
treatment
cours
day
blactam
day
azithromycin
best
studi
although
shorter
cours
studi
show
differ
acut
cure
relaps
rate
group
shorter
cours
acknowledg
effect
particularli
milder
case
although
prolong
cours
may
requir
pathogen
camrsa
similarli
random
control
studi
evalu
optimum
time
switch
parenter
oral
therapi
henc
idsa
bt
guidelin
provid
statement
recommend
although
canadian
guidelin
recommend
switch
parenter
oral
therapi
day
patient
afebril
without
complic
antimicrobialresist
streptococcu
pneumonia
recogn
problem
sinc
hope
heptaval
pneumococc
conjug
vaccin
approach
common
bacteri
infect
contain
serotyp
account
penicillinresist
pneumococc
isol
unit
state
would
decreas
antimicrobialresist
pneumococci
commun
seen
margin
success
one
longitudin
surveil
program
show
penicillinresist
isol
decreas
intermedi
penicillin
resist
increas
introduct
effect
antibiot
resist
clinic
outcom
children
less
evid
pneumococc
pneumonia
penicillinresist
penicillinsensit
associ
differ
outcom
hospit
cours
complic
associ
antimicrobi
resist
treatment
failur
yet
shown
children
minim
antimicrobi
resist
idsa
recommend
limit
antibiot
exposur
use
antibiot
narrow
spectrum
activ
shortest
effect
durat
howev
none
recommend
base
strongqual
evid
fluoroquinolon
gener
avoid
children
younger
year
concern
arthropathi
experi
use
treat
children
varieti
seriou
infecti
diseas
led
consensu
statement
fluoroquinolon
treat
specif
infect
children
safe
effect
may
consid
altern
therapi
seriou
infecti
diseas
bradley
colleagu
enrol
children
month
year
cap
noninferior
trial
show
similar
cure
rate
levofloxacin
compar
drug
fiftytwo
percent
children
treat
levofloxacin
experienc
advers
event
compar
comparatortr
children
musculoskelet
advers
event
arthralgia
myalgia
experienc
versu
compar
group
receiv
current
standard
care
antibiot
none
differ
statist
signific
era
emerg
drug
resist
fluoroquinolon
may
effect
altern
therapi
treat
children
cap
children
cap
adequ
therapi
clinic
improv
within
hour
improv
possibl
complic
consid
includ
pleural
effus
empyema
necrot
pneumonia
septicemia
metastat
infect
staphylococcu
aureu
caus
osteomyel
septic
arthriti
hemolyticurem
syndrom
complic
requir
investig
possibl
hospit
children
sever
pneumonia
empyema
lung
abscess
follow
discharg
complet
resolut
clinic
cxr
vaccin
play
crucial
part
prevent
pneumonia
pertussi
caus
pneumonia
report
case
doubl
report
case
younger
month
pneumonia
complic
measl
occur
depend
studi
base
commun
hospit
set
half
measlesrel
pneumonia
caus
bacteri
superinfect
contribut
death
measl
influenza
vaccin
prevent
influenzaassoci
pneumonia
hospit
includ
pneumococc
camrsa
superinfect
pneumococc
conjug
vaccin
decreas
radiolog
confirm
pneumonia
vaccineserotyp
bacterem
pneumonia
distribut
pneumococc
conjug
vaccin
may
address
common
replac
serotyp
increas
sinc
introduct
pneumococc
conjug
vaccin
unit
state
particularli
contain
addit
serotyp
associ
empyema
necrot
pneumonia
thu
hope
number
complic
decreas
highrisk
infant
rsvspecif
monoclon
antibodi
decreas
risk
sever
pneumonia
hospit
pneumonia
occur
often
earli
childhood
age
except
adult
older
year
kill
children
diseas
worldwid
central
clinic
issu
cap
children
diagnosi
typic
microbiolog
isol
rather
infer
deduct
clinic
symptom
sign
support
radiographi
serum
laboratori
test
approach
requir
gener
pediatrician
high
level
suspicion
attempt
discern
caus
bacteri
viral
implic
antimicrobi
manag
cap
chang
caus
manag
approach
molecular
diagnost
becom
avail
wellperform
trial
conduct
despit
find
although
guidelin
avail
patient
sever
pediatr
cap
recommend
mild
moder
case
constitut
case
seen
gener
pediatrician
base
evid
poor
moder
qualiti
situat
lead
overtreat
given
imprecis
diagnost
method
avail
unnecessari
antibiot
treatment
remain
substanti
gap
evid
optimum
manag
pediatr
cap
appropri
criteria
hospit
refer
standard
identifi
case
need
antibiot
constitut
optim
antibiot
therapi
